

WHAT IS CLAIMED IS:

1. An affinity binding entity comprising an antigen binding domain comprising:

(i) CDR sequences of an immunoglobulin heavy chain which are N-C ordered:

CDR1 HC	SEQ ID NO: 341	GYWIE
CDR2 HC	SEQ ID NO: 342	EILPGSGGTNYNEKFKG
CDR3 HC	SEQ ID NO: 343	DSNSFTY; and

(ii) CDR sequences of an immunoglobulin light chain which are N-C ordered:

CDR1 LC	SEQ ID NO: 335	SVSSSVDYIH
CDR2 LC	SEQ ID NO: 336	STSILAS
CDR3 LC	SEQ ID NO: 337	QQRSSYPPT

said affinity binding entity capable of binding HLA-A2/ MAGE-A4₂₃₀₋₂₃₉ in an MHC restricted manner.

2. The affinity binding entity of claim 1, being selected from the group consisting of an antibody, a T-cell receptor (TCR), and a chimeric antigen receptor (CAR).

3. The affinity binding entity of claim 1, being an antibody.

4. The affinity binding entity of claim 1, being a TCR.

5. The affinity binding entity of claim 1, being a CAR.

6. The affinity binding entity of claim 1, being a soluble entity.

7. The affinity binding entity of claim 2, being a humanized antibody.

8. The affinity binding entity of claim 1, comprising a therapeutic moiety.

9. The affinity binding entity of claim 2, comprising a therapeutic moiety.

10. The affinity binding entity of claim 1, comprising a detectable moiety.

11. The affinity binding entity of claim 2, wherein said antibody is a single chain antibody, a bi-specific antibody, or a full-length antibody.

12. An expression vector comprising a polynucleotide comprising a nucleic acid sequence encoding the affinity binding entity of claim 31 operably linked to a cis-acting regulatory element.
13. A cell comprising the expression vector of claim 12.
14. An *in vitro* method of detecting a cancer cell, comprising contacting the cell with the antibody of claim 2, under conditions which allow immunocomplex formation, wherein a presence of said immunocomplex, or level thereof, is indicative of the cancer cell.
15. An *ex vivo* method of diagnosing cancer in a subject in need thereof, comprising contacting a cell of the subject with the antibody of claim 2, under *ex vivo* conditions which allow immunocomplex formation, wherein a presence of said immunocomplex or level thereof is indicative of the cancer.
16. An affinity binding entity of claim 1 for use in the treatment of cancer.
17. The expression vector of claim 12, for use in the treatment of cancer.
18. The cell of claim 13, for use in the treatment of cancer.
19. The affinity binding entity of claim 2, for use as a medicament.
20. The expression vector of claim 12, for use as a medicament.
21. The cell of claim 13, for use as a medicament.